Robert Geho is a co-founder and CEO of Diasome Pharmaceuticals, Inc., focused on the clinical and commercial development of breakthrough therapies for diabetes and obesity. In his role at Diasome, he leads the management and strategic direction of the Company’s targeted insulin therapies, novel Type 2 diabetes technology, and oral therapy for obesity. In addition to his responsibilities at Diasome, he is a co-founder and director of SDG, Inc., a nanotechnology therapeutics company that is an Equity Partner Company of the Cleveland Clinic Foundation in Cleveland, Ohio. Mr. Geho has led or co-led multiple rounds of financing for several biotechnology companies, and he has been a key participant in the formation of multiple life sciences focused companies. He received both his undergraduate degree and an MBA from Case Western Reserve University.
Here are two 2019 press releases from Diasome. Good to see their effort and their product is still alive. Hard to believe that it’s been five years since this video interview.